380 reports of this reaction
2.3% of all ATROPINE reports
#9 most reported adverse reaction
BRADYCARDIA is the #9 most commonly reported adverse reaction for ATROPINE, manufactured by Meridian Medical Technologies LLC. There are 380 FDA adverse event reports linking ATROPINE to BRADYCARDIA. This represents approximately 2.3% of all 16,519 adverse event reports for this drug.
Patients taking ATROPINE who experience bradycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BRADYCARDIA is a less commonly reported adverse event for ATROPINE, but still significant enough to appear in the safety profile.
In addition to bradycardia, the following adverse reactions have been reported for ATROPINE:
The following drugs have also been linked to bradycardia in FDA adverse event reports:
BRADYCARDIA has been reported as an adverse event in 380 FDA reports for ATROPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BRADYCARDIA accounts for approximately 2.3% of all adverse event reports for ATROPINE, making it a notable side effect.
If you experience bradycardia while taking ATROPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.